267 related articles for article (PubMed ID: 27916909)
1. Dysregulated Homeostasis of Acetylcholine Levels in Immune Cells of RR-Multiple Sclerosis Patients.
Di Bari M; Reale M; Di Nicola M; Orlando V; Galizia S; Porfilio I; Costantini E; D'Angelo C; Ruggieri S; Biagioni S; Gasperini C; Tata AM
Int J Mol Sci; 2016 Nov; 17(12):. PubMed ID: 27916909
[TBL] [Abstract][Full Text] [Related]
2. Profiling of Canonical and Non-Traditional Cytokine Levels in Interferon-β-Treated Relapsing-Remitting-Multiple Sclerosis Patients.
D'Angelo C; Reale M; Costantini E; Di Nicola M; Porfilio I; de Andrés C; Fernández-Paredes L; Sánchez-Ramón S; Pasquali L
Front Immunol; 2018; 9():1240. PubMed ID: 29915590
[TBL] [Abstract][Full Text] [Related]
3. Nicotinic receptor activation negatively modulates pro-inflammatory cytokine production in multiple sclerosis patients.
Reale M; Di Bari M; Di Nicola M; D'Angelo C; De Angelis F; Velluto L; Tata AM
Int Immunopharmacol; 2015 Nov; 29(1):152-7. PubMed ID: 26209886
[TBL] [Abstract][Full Text] [Related]
4. Relation between pro-inflammatory cytokines and acetylcholine levels in relapsing-remitting multiple sclerosis patients.
Reale M; de Angelis F; di Nicola M; Capello E; di Ioia M; Luca Gd; Lugaresi A; Tata AM
Int J Mol Sci; 2012 Oct; 13(10):12656-64. PubMed ID: 23202919
[TBL] [Abstract][Full Text] [Related]
5. Functional variability in butyrylcholinesterase activity regulates intrathecal cytokine and astroglial biomarker profiles in patients with Alzheimer's disease.
Darreh-Shori T; Vijayaraghavan S; Aeinehband S; Piehl F; Lindblom RP; Nilsson B; Ekdahl KN; Långström B; Almkvist O; Nordberg A
Neurobiol Aging; 2013 Nov; 34(11):2465-81. PubMed ID: 23759148
[TBL] [Abstract][Full Text] [Related]
6. Circulating levels of interleukin-17A, tumor necrosis factor-alpha, interleukin-18, interleukin-10, and cognitive performance of patients with relapsing-remitting multiple sclerosis.
Trenova AG; Slavov GS; Draganova-Filipova MN; Mateva NG; Manova MG; Miteva LD; Stanilova SA
Neurol Res; 2018 Mar; 40(3):153-159. PubMed ID: 29297273
[TBL] [Abstract][Full Text] [Related]
7. Cytokine profile, Foxp3 and nuclear factor-kB ligand levels in multiple sclerosis subtypes.
Alatab S; Maghbooli Z; Hossein-Nezhad A; Khosrofar M; Mokhtari F
Minerva Med; 2011 Dec; 102(6):461-8. PubMed ID: 22193377
[TBL] [Abstract][Full Text] [Related]
8. The role of Th17 cells in patients with relapsing-remitting multiple sclerosis: interleukin-17A and interleukin-17F serum levels.
Babaloo Z; Aliparasti MR; Babaiea F; Almasi S; Baradaran B; Farhoudi M
Immunol Lett; 2015 Apr; 164(2):76-80. PubMed ID: 25625963
[TBL] [Abstract][Full Text] [Related]
9. Tumor necrosis factor-alfa and interleukin-4 in cerbrospinal fluid and plasma in different clinical forms of multiple sclerosis.
Obradović D; Kataranovski M; Dincić E; Obradović S; Colić M
Vojnosanit Pregl; 2012 Feb; 69(2):151-6. PubMed ID: 22500369
[TBL] [Abstract][Full Text] [Related]
10. Alterations in the cholinesterase and adenosine deaminase activities and inflammation biomarker levels in patients with multiple sclerosis.
Polachini CR; Spanevello RM; Casali EA; Zanini D; Pereira LB; Martins CC; Baldissareli J; Cardoso AM; Duarte MF; da Costa P; Prado AL; Schetinger MR; Morsch VM
Neuroscience; 2014 Apr; 266():266-74. PubMed ID: 24508813
[TBL] [Abstract][Full Text] [Related]
11. Cytokine profile in relapsing‑remitting multiple sclerosis patients and the association between progression and activity of the disease.
Kallaur AP; Oliveira SR; Colado Simão AN; Delicato de Almeida ER; Kaminami Morimoto H; Lopes J; de Carvalho Jennings Pereira WL; Marques Andrade R; Muliterno Pelegrino L; Donizete Borelli S; Kaimen-Maciel DR; Reiche EM
Mol Med Rep; 2013 Mar; 7(3):1010-20. PubMed ID: 23292766
[TBL] [Abstract][Full Text] [Related]
12. Dysregulated neurotrophin mRNA production by immune cells of patients with relapsing remitting multiple sclerosis.
Urshansky N; Mausner-Fainberg K; Auriel E; Regev K; Farhum F; Karni A
J Neurol Sci; 2010 Aug; 295(1-2):31-7. PubMed ID: 20541775
[TBL] [Abstract][Full Text] [Related]
13. Acetylcholinesterase and butyrylcholinesterase as possible markers of low-grade systemic inflammation.
Das UN
Med Sci Monit; 2007 Dec; 13(12):RA214-21. PubMed ID: 18049445
[TBL] [Abstract][Full Text] [Related]
14. Possible Correlation between Cholinergic System Alterations and Neuro/Inflammation in Multiple Sclerosis.
Gatta V; Mengod G; Reale M; Tata AM
Biomedicines; 2020 Jun; 8(6):. PubMed ID: 32521719
[TBL] [Abstract][Full Text] [Related]
15. Butyrylcholinesterase activity in multiple sclerosis neuropathology.
Darvesh S; Leblanc AM; Macdonald IR; Reid GA; Bhan V; Macaulay RJ; Fisk JD
Chem Biol Interact; 2010 Sep; 187(1-3):425-31. PubMed ID: 20122907
[TBL] [Abstract][Full Text] [Related]
16. Altered Serum Cytokine Profiles in Relapse Phase of Relapsing-Remitting Multiple Sclerosis.
Peiravian F; Rajaian H; Samiei A; Gholijani N; Gharesi-Fard B; Mokaram P; Rahimi-Jaberi A; Kamali Sarvestani E
Iran J Immunol; 2016 Sep; 13(3):186-96. PubMed ID: 27671510
[TBL] [Abstract][Full Text] [Related]
17. Butyrylcholinesterase and Acetylcholinesterase polymorphisms in Multiple Sclerosis patients: implication in peripheral inflammation.
Reale M; Costantini E; Di Nicola M; D'Angelo C; Franchi S; D'Aurora M; Di Bari M; Orlando V; Galizia S; Ruggieri S; Stuppia L; Gasperini C; Tata AM; Gatta V
Sci Rep; 2018 Jan; 8(1):1319. PubMed ID: 29358722
[TBL] [Abstract][Full Text] [Related]
18. CXCL11 (Interferon-inducible T-cell alpha chemoattractant) and interleukin-18 in relapsing-remitting multiple sclerosis patients treated with methylprednisolone.
Szczuciński A; Kalinowska A; Losy J
Eur Neurol; 2007; 58(4):228-32. PubMed ID: 17827967
[TBL] [Abstract][Full Text] [Related]
19. Chitinase effects on immune cell response in neuromyelitis optica and multiple sclerosis.
Correale J; Fiol M
Mult Scler; 2011 May; 17(5):521-31. PubMed ID: 21159721
[TBL] [Abstract][Full Text] [Related]
20. A critical role for expression of atypical chemokine receptor 2 in multiple sclerosis: A preliminary project.
Saçmacı H; Sabah Özcan S
Mult Scler Relat Disord; 2020 Feb; 38():101524. PubMed ID: 31770664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
